Publications by authors named "Gerald Lossaint"

Claim this Profile
O
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.
Alexandra Fauvre, Chiara Ursino, Veronique Garambois, Elodie Culerier, Louis-Antoine Milazzo, Gérald Lossaint

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.
Alexia Mirandola, Andrei Kudriavtsev, Catalina Isabel Cofre Muñoz, Raquel Comas Navarro, Marco Macagno, Gerald Lossaint

EBioMedicine· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to mediate senescence onset after G2 arrest.
Gérald Lossaint, Anđela Horvat, Véronique Gire, Katarina Bačević, Karim Mrouj

J Cell Sci· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects.
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier, Marie Alexandre, Séverine Guiu, Gerald Lossaint

Pharmaceutics· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The human telomeric proteome during telomere replication.
Chih-Yi Gabriela Lin, Anna Christina Näger, Thomas Lunardi, Aleksandra Vančevska, Gérald Lossaint

Nucleic Acids Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy.
Fanny Leenhardt, Marie Alexandre, Severine Guiu, Stephane Pouderoux, Melanie Beaujouin, Gerald Lossaint

Cancer Chemother Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM.
Guillaume Belthier, Zeinab Homayed, Fanny Grillet, Christophe Duperray, Julie Vendrell, Gérald Lossaint

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage.
Katarina Bačević, Gérald Lossaint, Thiziri Nait Achour, Virginie Georget, Daniel Fisher

Sci Rep· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TZAP or not to zap telomeres.
Gérald Lossaint, Joachim Lingner

Science· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling.
Gérald Lossaint, Marion Larroque, Cyril Ribeyre, Nicole Bec, Christian Larroque

Mol Cell· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confluence-induced cell cycle exit involves pre-mitotic CDK inhibition by p27(Kip1) and cyclin D1 downregulation.
Anne-Amandine Chassot, Gerald Lossaint, Laurent Turchi, Guerrino Meneguzzi, Daniel Fisher

Cell Cycle· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis